HC Wainwright Issues Optimistic Forecast for AGIO Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Investment analysts at HC Wainwright lifted their Q1 2026 earnings per share estimates for Agios Pharmaceuticals in a research report issued on Thursday, February 12th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will post earnings per share of ($1.82) for the quarter, up from their prior estimate of ($1.86). HC Wainwright currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q2 2026 earnings at ($1.66) EPS, Q3 2026 earnings at ($1.63) EPS, Q4 2026 earnings at ($1.58) EPS, FY2026 earnings at ($6.68) EPS, FY2027 earnings at ($5.48) EPS, FY2028 earnings at ($4.24) EPS and FY2029 earnings at ($2.49) EPS.

Other research analysts have also recently issued reports about the stock. Bank of America increased their price objective on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. The Goldman Sachs Group cut their target price on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a research report on Thursday, November 20th. JPMorgan Chase & Co. lifted their price target on Agios Pharmaceuticals from $20.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, January 6th. Leerink Partners upped their price objective on Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, December 26th. Finally, Wall Street Zen raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $39.78.

Agios Pharmaceuticals Trading Down 0.5%

Agios Pharmaceuticals stock opened at $27.82 on Monday. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of -3.91 and a beta of 0.91. The company’s 50-day moving average price is $27.42 and its two-hundred day moving average price is $33.90.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP grew its position in Agios Pharmaceuticals by 485.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock worth $99,203,000 after purchasing an additional 2,049,287 shares in the last quarter. MPM Bioimpact LLC purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at $35,478,000. State Street Corp raised its position in Agios Pharmaceuticals by 37.4% during the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock valued at $84,604,000 after buying an additional 845,433 shares during the period. TCG Crossover Management LLC raised its position in Agios Pharmaceuticals by 105.2% during the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after buying an additional 733,038 shares during the period. Finally, Capital International Investors purchased a new stake in Agios Pharmaceuticals in the 4th quarter worth about $19,159,000.

Insider Activity at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 18,703 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total value of $506,664.27. Following the transaction, the chief executive officer owned 136,583 shares of the company’s stock, valued at approximately $3,700,033.47. This trade represents a 12.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Sarah Gheuens sold 2,932 shares of the company’s stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the sale, the insider directly owned 64,795 shares of the company’s stock, valued at $1,755,296.55. This represents a 4.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 33,303 shares of company stock valued at $901,977 over the last ninety days. Company insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.